Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
3.605
+0.080 (2.27%)
May 6, 2025, 9:43 AM EDT - Market open
Inventiva Revenue
In the year 2024, Inventiva had annual revenue of 14.09M EUR, down -38.24%. Inventiva had revenue of 11.36M in the half year ending December 31, 2024, a decrease of -26.34%.
Revenue (ttm)
14.09M EUR
Revenue Growth
-38.24%
P/S Ratio
23.69
Revenue / Employee
119,441 EUR
Employees
118
Market Cap
345.72M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
IVA News
- 1 day ago - Inventiva secures the €116 million second tranche of its structured financing of up to €348 million - GlobeNewsWire
- 5 days ago - Combined General Meeting of May 22, 2025 - Availability of the preparatory documents - GlobeNewsWire
- 11 days ago - Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor - GlobeNewsWire
- 20 days ago - Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F - GlobeNewsWire
- 4 weeks ago - Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis - GlobeNewsWire
- 5 weeks ago - Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Inventiva reports its 2024 full year results and provides a business update - GlobeNewsWire
- 6 weeks ago - Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results - GlobeNewsWire